ReviewStem cells translational medicine2015
The DISCUSS Project: Revised Points to Consider for the Derivation of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens.
Review in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- When does broad consent expire? A temporal validity framework for biobank samples in induced pluripotent stem cell research.Research square · 2026Article
- Community and bioethicists' perspectives on iPSC research with biobanked samples collected using broad consent.Stem cell reports · 2025Review
- What does "appropriate scientific justification" mean for the review of human pluripotent stem cell, embryo, and related research?Stem cell reports · 2025Article
- Human pluripotent stem cell registry: Operations, role and current directions.Cell proliferation · 2022Review
- Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development.Cell proliferation · 2022Article
- Human organoids: a new dimension in cell biology.Molecular biology of the cell · 2019Article
- Adapting Cord Blood Collection and Banking Standard Operating Procedures for HLA-Homozygous Induced Pluripotent Stem Cells Production and Banking for Clinical Application.Journal of clinical medicine · 2019Review
- The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks.Regenerative medicine · 2017Article
- A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine.NPJ Regenerative medicine · 2017Review
- Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.Regenerative therapy · 2016Review
- Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells.Molecular and cellular neurosciences · 2016Review
- Need for DISCUSS(ion).Stem cells translational medicine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Human somatic cell reprogramming is a leading technology for accelerating disease modeling and drug discovery. The Deriving Induced Stem Cells Using Stored Specimens (DISCUSS) project is a consensus-building initiative designed to consider how human somatic cells obtained under general biomedical research protocols can be used in induced pluripotent stem cell (iPSC) derivation. We previously published a draft list of points to consider for the use of previously collected specimens in iPSC research and then initiated a structured feedback and comment process. Here, we present a summary of this feedback and revised list of points to consider.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.